EADV: Investigational biologic rocks psoriasis world
COPENHAGEN – An investigational biologic agent that selectively inhibits the p19 subunit of interleukin-23 was the talk of the 2015 EADV congress based upon its striking outperformance of ustekinumab in a head-to-head phase II study in psoriasis patients.
Not only did the investigational agent,...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Dermatology | Politics | Psoriasis | Skin | Stelara | Study